Outcome of Patients Receiving Extracorporeal Photopheresis for Steroid Resistant Acute and Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Conclusion:We confirm that ECP is an effective treatment for GVHD in a good proportion of patients with overall response rate of 59%. Interestingly, we observed a better PFS in patients receiving ECP for longer time as in the case of chronic GVHD, which could be related to the GVL effect itself but also a possible involvement of the ECP. As patients with advanced phase of GVHD were poor responders, we suggest that an early use of ECP in the acute phase of the inflammation before organ damage, could lead to optimal results.DisclosuresMichallet: Novartis: Research Funding; Octapharma: Membership on an entity's Board of Directors or advisory committees; Chugai: Consultancy. Nicolini: Incyte: Consultancy, Honoraria, Speakers Bureau; Sun Pharma: Consultancy; Bristol-Myers Squibb: Consultancy, Honoraria, Speakers Bureau.
Source: Blood - Category: Hematology Authors: Tags: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution Source Type: research

Related Links:

Authors: Zi F, Yu L, Shi Q, Tang A, Cheng J Abstract B-cell receptor (BCR) signaling is important for the development and maturation of normal B-cells and plays a key role in B-cell malignancies. Bruton's tyrosine kinase (BTK), a crucial terminal kinase enzyme in BCR signaling, has emerged as an attractive target and has been successfully applied in the treatment of hematological malignancies. Ibrutinib, a BTK inhibitor, has demonstrated marked efficacy and tolerability in treatment-naïve, relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL). Ibru...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
rer S Abstract In this review article, we present recent updates on the hematological tumor microenvironment following the 3rd Scientific Workshop on the Haematological Tumour Microenvironment and its Therapeutic Targeting organized by the European School of Hematology, which took place at the Francis Crick Institute in London in February 2019. This review article is focused on recent scientific advances highlighted in the invited presentations at the meeting, which encompass the normal and malignant niches supporting hematopoietic stem cells and their progeny. Therefore, for the sake of focus it does not discuss ...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
AbstractLeukemia is one of the most aggressive hematological malignancies. Leukemia stem cells account for the poor prognosis and relapse of the disease. Decades of investigations have been performed to figure out how to eradicate the leukemia stem cells. It has also been known that cancer cells especially solid cancer cells use energy differently than most of the cell types. The same thing happens to leukemia. Since there are metabolic differences between the hematopoietic stem cells and their immediate descendants, we aim at manipulating the energy sources with which that could have an effect on leukemia stem cells while...
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
Markus Hartl* and Rainer Schneider Center of Molecular Biosciences (CMBI), Institute of Biochemistry, University of Innsbruck, Innsbruck, Austria The neuronal proteins GAP43 (neuromodulin), MARCKS, and BASP1 are highly expressed in the growth cones of nerve cells where they are involved in signal transmission and cytoskeleton organization. Although their primary structures are unrelated, these signaling proteins share several structural properties like fatty acid modification, and the presence of cationic effector domains. GAP43, MARCKS, and BASP1 bind to cell membrane phospholipids, a process reversibly regulate...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study proposed a pilot study of a new tool for a reliable and accurate stratification of patients with acute leukemia based on an integrative model of leukemia behavior, cell characterization, and clinical features, in addition, to an evaluation of intra-tumor and inter-tumor heterogeneity. Together our approach allows us to introduce an integrative quantitative approach to use zebrafish and tumor characterization as a prediction tool for the behavior of acute leukemia in young adults. Materials and Methods Animal Care and Handling Zebrafish wild-type (A/B and TAB5) adults were raised and maintained according to st...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionHistory of CLL did not independently affect OS in t-MDS patients beyond IPSS-R score.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 23 January 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Krzysztof Mądry, Karol Lis, Przemysław Biecek, Magda Młynarczyk, Jagoda Rytel, Michał Górka, Piotr Kacprzyk, Magdalena Dutka, Marek Rodzaj, Łukasz Bołkun, Dorota Krochmalczyk, Ewa Łątka, Joanna Drozd-Sokołowska, Anna Waszczuk-Gajda, Wanda Knopińska-Posłuszny, Anna Kopińska, Edyta Subocz, Anna Masternak, Renata Guzicka-Kazimierczak, Lidia GilAbstractBackgroundMyelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) patients, including those treated wit...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 23 January 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Krzysztof Mądry, Karol Lis, Przemysław Biecek, Magda Młynarczyk, Jagoda Rytel, Michał Górka, Piotr Kacprzyk, Magdalena Dutka, Marek Rodzaj, Łukasz Bołkun, Dorota Krochmalczyk, Ewa Łątka, Joanna Drozd-Sokołowska, Anna Waszczuk-Gajda, Wanda Knopińska-Posłuszny, Anna Kopińska, Edyta Subocz, Anna Masternak, Renata Guzicka-Kazimierczak, Lidia GilAbstractMyelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute leukemia (AML) patients, including those treated with azacitidine, are ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
The aim of our study was to identify myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute leukemia patients with higher infectious risk during azacitidine treatment. We retrospectively analyzed 298 patients and developed the Azacitidine Infection Risk Model. We selected a subset with high risk for infection (infection rate, 73% vs. 25%) and worse clinical outcome (survival, 8 vs. 29 months) among azacitidine-treated patients.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
In conclusion, 96.5% of patients with hematologic malignancies have adequate tissue for comprehensive genomic profiling. Most patients had unique molecular signatures, and 75% had alterations that may be pharmacologically tractable with gene- or immune-targeted agents.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Acute Leukemia | Cancer & Oncology | Chronic Leukemia | Hematology | Leukemia | Liver | Liver Transplant | Methotrexate | Myelodysplastic Syndrome | Myeloma | Pharmaceuticals | Prednisolone | Restasis | Skin | Skin Graft | Stem Cell Therapy | Stem Cells | Study | Transplants | Urology & Nephrology